| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 603.13% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
| 07/20/2023 | — | HC Wainwright & Co. | Reiterates | Buy → Buy | |
| 06/29/2023 | 603.13% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
| 05/02/2023 | 603.13% | HC Wainwright & Co. | → $54 | Reiterates | → Buy |
| 03/31/2023 | 603.13% | HC Wainwright & Co. | $50 → $54 | Maintains | Buy |
| 02/09/2023 | 264.58% | BTIG | $35 → $28 | Maintains | Buy |
| 02/09/2023 | 551.04% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 02/06/2023 | 551.04% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 01/03/2023 | 551.04% | HC Wainwright & Co. | $42 → $50 | Maintains | Buy |
| 12/06/2022 | 43.23% | Cantor Fitzgerald | $16 → $11 | Downgrades | Overweight → Neutral |
| 06/23/2022 | 420.83% | Berenberg | → $40 | Initiates Coverage On | → Buy |
| 02/02/2022 | 446.88% | HC Wainwright & Co. | $39 → $42 | Maintains | Buy |
| 09/23/2021 | 355.73% | BTIG | → $35 | Initiates Coverage On | → Buy |
| 06/28/2021 | 407.81% | HC Wainwright & Co. | $25 → $39 | Maintains | Buy |
| 06/15/2021 | 225.52% | HC Wainwright & Co. | $17 → $25 | Maintains | Buy |
| 02/23/2021 | 225.52% | Cantor Fitzgerald | $10 → $25 | Reiterates | → Overweight |
| 12/16/2020 | 121.35% | HC Wainwright & Co. | $14 → $17 | Maintains | Buy |
| 10/21/2020 | 82.29% | HC Wainwright & Co. | $12 → $14 | Maintains | Buy |
| 09/28/2020 | 56.25% | Ladenburg Thalmann | → $12 | Initiates Coverage On | → Buy |
| 03/16/2020 | 56.25% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 07/24/2019 | 108.33% | Dawson James | → $16 | Initiates Coverage On | → Buy |
| 06/18/2019 | 30.21% | Janney Montgomery Scott | → $10 | Initiates Coverage On | → Buy |
What is the target price for Anavex Life Sciences (AVXL)?
The latest price target for Anavex Life Sciences (NASDAQ: AVXL) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $54.00 expecting AVXL to rise to within 12 months (a possible 603.13% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Anavex Life Sciences (AVXL)?
The latest analyst rating for Anavex Life Sciences (NASDAQ: AVXL) was provided by HC Wainwright & Co., and Anavex Life Sciences reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Anavex Life Sciences (AVXL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anavex Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anavex Life Sciences was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
Is the Analyst Rating Anavex Life Sciences (AVXL) correct?
While ratings are subjective and will change, the latest Anavex Life Sciences (AVXL) rating was a reiterated with a price target of $0.00 to $54.00. The current price Anavex Life Sciences (AVXL) is trading at is $7.68, which is within the analyst's predicted range.